Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

2024-512586-13-00 Protocol M24-893 Human pharmacology (Phase I) - First administration to humans Ended

End 22 Sep 2025 · Status Ended · 3 EU/EEA countries · 7 sites · Protocol M24-893

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 157
Countries 3
Sites 7

Non-Hodgkin's Lymphoma

Key facts

Sponsor
AbbVie Deutschland GmbH & Co. KG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
completed 22 Sep 2025
Decision date (initial)
2025-08-11
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-512586-13-00
ClinicalTrials.gov
NCT06667687

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Hodgkin's Lymphoma

VersionLevelCodeTermSystem organ class
25.0 LLT 10086816 B-cell non-Hodgkin´s lymphoma refractory 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

AbbVie Deutschland GmbH & Co. KG

Sponsor organisation
AbbVie Deutschland GmbH & Co. KG
Address
Knollstrasse
City
Ludwigshafen Am Rhein
Postcode
67061
Country
Germany

Scientific contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Public contact point

Organisation
AbbVie Deutschland GmbH & Co. KG
Contact name
Global Clinical Trials Helpdesk

Locations

3 EU/EEA countries · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ended 16 2
Spain Ended 24 3
Sweden Ended 16 2
Rest of world
United States, Israel, Japan, Australia, United Kingdom
101

Investigational sites

Denmark

2 sites · Ended
Rigshospitalet
1202: Department of Haematology and Phase 1 Unit., Blegdamsvej 9, 2100, Copenhagen Oe
Region Midtjylland
1201: Hematology, Palle Juul-Jensens Boulevard 99, 8200, Aarhus N

Spain

3 sites · Ended
Hospital Universitario Hm Sanchinarro
9003: Hematología, Calle Ona 10, 28050, Madrid
Hospital Universitari Vall D Hebron
9002: Hematología, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
9001: Hematología, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Sweden

2 sites · Ended
Region Skane Skanes Universitetssjukhus
1302: Endocrinology, Entregatan 7, 222 42, Lund
Karolinska University Hospital
1301: Hematologiskt Centrum, Eugeniavagen 3, 171 64, Solna

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-29 Denmark Acceptable with conditions
2025-08-07
2025-08-11